Lyme neuroborreliosis in a patient treated with TNF-alpha inhibitor.
A 57-year-old woman, receiving TNF-alpha inhibitor adalimumab for psoriasis, presented with early Lyme neuroborreliosis (Bannwarth's syndrome). Discontinuation of adalimumab and 14-day therapy with ceftriaxone resulted in a smooth course and favorable outcome of Lyme borreliosis. This is the first report on Lyme neuroborreliosis in a patient treated with TNF-alpha inhibitor.
General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia.
Maja Ivartnik
MI
Merkac
Department of Infectious Diseases, University Medical Centre Ljubljana, Japljeva 2, 1525, Ljubljana, Slovenia.
Janez
J
Tomazic
Department of Infectious Diseases, University Medical Centre Ljubljana, Japljeva 2, 1525, Ljubljana, Slovenia. franc.strle@kclj.si.
Franc
F
Strle
D000068879:Adalimumab / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002443:Ceftriaxone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D020852:Lyme Neuroborreliosis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology*; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D007155:Immunologic Factors; D002443:Ceftriaxone; D000068879:Adalimumab
Adalimumab; Bannwarth’s syndrome; Lyme borreliosis; Lyme neuroborreliosis; TNF-α inhibitor